# Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

> **NCT03963193** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 112 (estimated)

## Conditions studied

- Gastrointestinal Neuroendocrine Tumor

## Interventions

- **DRUG:** Etoposide
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03963193
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2020-06-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2019-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03963193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03963193, "Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03963193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*